Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)’s stock price has gone decline by -7.48 in comparison to its previous close of 235.57, however, the company has experienced a 6.83% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-04-30 that MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy too. Shortages of semaglutide and tirzepatide could help Rezdiffra’s initial launch.
Is It Worth Investing in Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Right Now?
Additionally, the 36-month beta value for MDGL is -0.43. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MDGL is 17.43M and currently, short sellers hold a 19.54% ratio of that float. The average trading volume of MDGL on May 08, 2024 was 574.17K shares.
MDGL’s Market Performance
MDGL’s stock has seen a 6.83% increase for the week, with a -12.34% drop in the past month and a 8.20% gain in the past quarter. The volatility ratio for the week is 5.80%, and the volatility levels for the past 30 days are at 5.49% for Madrigal Pharmaceuticals Inc The simple moving average for the past 20 days is -1.47% for MDGL’s stock, with a 8.20% simple moving average for the past 200 days.
Analysts’ Opinion of MDGL
Many brokerage firms have already submitted their reports for MDGL stocks, with BofA Securities repeating the rating for MDGL by listing it as a “Underperform.” The predicted price for MDGL in the upcoming period, according to BofA Securities is $150 based on the research report published on April 22, 2024 of the current year 2024.
B. Riley Securities, on the other hand, stated in their research note that they expect to see MDGL reach a price target of $270, previously predicting the price at $155. The rating they have provided for MDGL stocks is “Neutral” according to the report published on March 15th, 2024.
Citigroup gave a rating of “Buy” to MDGL, setting the target price at $382 in the report published on March 06th of the current year.
MDGL Trading at -9.32% from the 50-Day Moving Average
After a stumble in the market that brought MDGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.39% of loss for the given period.
Volatility was left at 5.49%, however, over the last 30 days, the volatility rate increased by 5.80%, as shares sank -12.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.28% lower at present.
During the last 5 trading sessions, MDGL rose by +6.83%, which changed the moving average for the period of 200-days by +1.02% in comparison to the 20-day moving average, which settled at $219.64. In addition, Madrigal Pharmaceuticals Inc saw -5.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDGL starting from FRIEDMAN PAUL A, who sale 26,270 shares at the price of $246.19 back on Apr 08 ’24. After this action, FRIEDMAN PAUL A now owns 185,735 shares of Madrigal Pharmaceuticals Inc, valued at $6,467,491 using the latest closing price.
Taub Rebecca, the Pres., R&D, and CMO of Madrigal Pharmaceuticals Inc, sale 2,676 shares at $245.99 during a trade that took place back on Apr 08 ’24, which means that Taub Rebecca is holding 458,999 shares at $658,258 based on the most recent closing price.
Stock Fundamentals for MDGL
The total capital return value is set at -0.73. Equity return is now at value -123.98, with -74.49 for asset returns.
Based on Madrigal Pharmaceuticals Inc (MDGL), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -2.79. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -66.71.
Currently, EBITDA for the company is -379.97 million with net debt to EBITDA at -0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.38.
Conclusion
In conclusion, Madrigal Pharmaceuticals Inc (MDGL) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
